ShapeShapeauthorShapecrossShapeShapeShapeGrouphamburgerhomeGroupmagnifyShapeShapeShapeShape

Audevard introduces Equioxx - the first equine NSAID in tablet form

New product provides a painless new development in equine medicine that promotes compliance

09 June 2021, at 2:00pm

Developing pain management in horses, Audevard Laboratories introduces the latest generation of a non-steroidal anti-inflammatory medicine in tablet form: Equioxx.

One tablet per day: a real change in the management of pain in horses.

With this new product, Audevard Laboratories provide a painless new development in equine medicine that promotes compliance. The tablet format allows the owner to administer directly to the horse with a treat in the palm of the hand: no need to mix with feed, minimising the risk of product loss or residual product being left behind.

In addition, the characteristics of firocoxib mean one tablet per 450-600kg is required per day. This once daily administration of a single tablet secures the compliance without increasing the price for the owner.

Firocoxib: Triple advantage of a latest generation molecule

Firocoxib, the molecule contained in Equioxx, is the latest generation anti-inflammatory medicine with three characteristics: Equal efficiency to flunixin and phenylbutazone, an efficacy period of 24 hours and a high cyclooxygenase 2 selectivity preserving the physiology of the horse.

Efficiency - Firocoxib has inhibitory action inflammatory mediators equivalent to flunixin. In clinical studies carried out in horses, the efficacy on pain is equal to flunixin and the improvement of lameness is equal to phenylbutazone.

Efficacy over time - Firocoxib is characterised by a long plasma life which gives it a concentration enabling 80 percent efficacy (EC80) 24 hours after the last administration. For comparison, firocoxib has an EC80 of 24h, meloxicam has an EC80 of 9h and phenylbutazone has an EC80 of less than 8h.

COX-2 selectivity - Firocoxib is the only COX-2 selective equine NSAID. It has a COX-1/COX-2 selectivity index of 265. The action is concentrated on the COX-2 enzymes, mainly responsible for inflammation, and acts very little on the COX-1 enzymes, mainly responsible for gastrointestinal and renal functions. For comparison, meloxicam is a COX-2 preferred NSAID and has a selectivity index of 3. Phenylbutazone and flunixin are COX-1 preferred NSAIDs and have a selectivity index of 0.3.

Ease of use, clinical efficacy, long duration of action and concentrated action on COX-2 are the strengths of Equioxx by Audevard, a new non-steroidal anti-inflammatory medicine in tablet form, available to equine veterinarians.

Equioxx Tablets provide assurance for the veterinarian, that with only one administration by hand per day, the horse will be relieved from pain for 24 hours. Lasting pain relief becomes painless.

For more information, contact Audevard directly.